BioInformatics, LLC New Market Report - Genomics Technologies

ARLINGTON, Va., Jan. 6, 2011 /PRNewswire/ -- BioInformatics, LLC announces the release of their newest market report:

Genomic Technologies:  Market Insights for Life Science Suppliers (#10-005)

This report is for life science suppliers who want to respond in a timely fashion to the rapidly changing market for genomic analysis products. In this study, BioInformatics LLC quantifies and characterizes the market for genetic analysis including those products used for genome-wide association studies (GWAS), copy number variation (CNV) analysis, genotyping and techniques such as microarrays, sequencing and real-time PCR.

Survey respondents indicate planned lab expenditures by vendor.  The following suppliers were provided as some of the choices in the survey:

Agilent Technologies

Affymetrix

Beckman Coulter

BD Biosciences

Bioneer

Bio-Rad

BioTrove

Cepheid

Eppendorf

GE Healthcare

Helicos Bioscience

Idaho Technology, Inc.

Illumina

Li-Cor Biosciences

Life Technologies

Luminex

Qiagen

Roche Applied Science

Sequenom

Stratagene

Techne



"In this study, we look at genetic analysis in current life science laboratories, the techniques and applications used, satisfaction and unmet needs with respect to current product offerings, budgets and predicted growth and future needs among life scientists," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services.  Dr. Zemlo adds that, "The information presented in this report will provide life science suppliers with information they can use to better meet their customers' needs as the field of genetic analysis continues to expand in new directions."

To learn more about these reports, a complimentary Executive Summary is available at

http://www.gene2drug.com/index.php?page=reports&id=211

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry.  By leveraging our professional social network of more than 50,000 life scientists, we have supported more than 300 companies and provided insights that lead to better business decisions.  Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

For more information contact:


Mary Follin

Manager, Marketing/Sales

BioInformatics, LLC

2111 Wilson Blvd., Suite 250

Arlington, VA  22201

703.778.3080 x13 (phone)

[email protected]ne2drug.com

http://www.gene2drug.com/



SOURCE BioInformatics, LLC

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.